The Wegovy Pill in the UK: What Women Should Know

For many women, GLP-1 medications have become closely associated with weekly injections. But that may soon begin to change.

A tablet version of semaglutide, the active ingredient used in Wegovy, is currently awaiting approval for weight management in the UK, and it is already generating significant interest across the obesity and metabolic health space.

While injectable GLP-1 medications remain the current standard, oral GLP-1 treatments could represent the next major step in widening access and offering more choice for patients.

Here is what we know so far about the upcoming Wegovy pill, what makes it different, and what it could mean for the future of weight management.

Is there a Wegovy pill available in the UK?

Not yet. In the UK, Wegovy is currently only approved as a weekly injection, not a pill.

What people call the "Wegovy pill" is an oral version of semaglutide that has been approved in the US, but it has not yet been licensed by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss. Most UK pharmacy and medical sources say it is unlikely to be available here before late 2026.

If you come across a website claiming to sell a Wegovy pill in the UK today, treat it with serious caution. It is not a regulated, licensed product in this country.

What is the Wegovy pill?

The upcoming Wegovy pill is an oral version of semaglutide, a GLP-1 medication already used in injectable treatments such as Wegovy and Ozempic.

Semaglutide works by mimicking a natural hormone in the body called GLP-1, which helps regulate appetite, hunger signals, blood sugar levels, feelings of fullness, and food cravings.

The tablet aims to deliver similar metabolic and appetite-regulating effects as injectable semaglutide, but in a once-daily pill format rather than a weekly injection.

‍

Is this a completely new medication?

Not entirely.

An oral form of semaglutide already exists for type 2 diabetes under the name Rybelsus. However, the higher-dose oral semaglutide being studied for weight management is designed specifically for obesity and weight-related health conditions, and requires its own separate MHRA review and approval.

How is a semaglutide pill absorbed differently from an injection?

Unlike injectable semaglutide, oral semaglutide needs to be absorbed through the stomach. Because of this, the tablet usually has stricter instructions around how it is taken.

Current oral semaglutide tablets are typically taken first thing in the morning, on an empty stomach, with a small amount of water, followed by a waiting period before eating or drinking. This routine may not suit everyone, which is why injections may still be preferable for some women despite the convenience of a pill.

Why isn't the Wegovy pill approved in the UK yet?

The US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) are separate bodies with independent review processes. A drug being approved in the US does not mean it is automatically approved in the UK.

For oral semaglutide to be licensed for weight loss here, the manufacturer Novo Nordisk must submit clinical trial data to the MHRA and go through a formal assessment process. As of now, no confirmed review timeline or approval date has been announced.

Is oral semaglutide approved anywhere else in the world?

Yes. The FDA in the United States has approved a higher-dose oral semaglutide specifically for chronic weight management. This is important context: the drug is not unproven,it has been through rigorous clinical trials and is already in use. The question is specifically about when the UK's own regulatory process will reach a conclusion.

When could the Wegovy pill become available in the UK?

The oral Wegovy-style pill is still awaiting regulatory approval for weight management in the UK. This means it is not yet licensed for obesity treatment here, timelines may still change, and access will depend on the MHRA's review and approval process.

Most UK pharmacy and medical sources suggest approval is unlikely before late 2026. However, interest across the healthcare industry is growing rapidly, and many experts believe oral GLP-1 medications could become a major part of obesity treatment in the coming years.

What would the Wegovy pill mean for women?

Why are so many women interested in an oral option? For many, the biggest barrier to starting a GLP-1 medication is the idea of injections. While most people adapt quickly to weekly injections, others dislike needles, worry about self-injecting, travel frequently, prefer tablets over injectable medications, or simply want more treatment choice.

An oral option could make GLP-1 treatment feel more accessible and convenient for some women. But convenience is only part of the story.

The growing interest in oral GLP-1 medications also reflects a wider shift in how obesity and metabolic health are being understood. Increasingly, obesity is being recognised as a complex biological and metabolic condition, not simply a matter of willpower.

Could the Wegovy pill benefit women with PCOS?

Polycystic ovary syndrome (PCOS) affects roughly one in ten women of reproductive age in the UK and is closely linked to insulin resistance, difficulty managing weight, and an elevated risk of type 2 diabetes. GLP-1 receptor agonists like semaglutide have shown promising results in women with PCOS, supporting weight loss and potentially improving hormonal and metabolic markers alongside it.

For women with PCOS who have avoided injectable treatments due to needle anxiety, an oral form of semaglutide could offer a more accessible route into this class of medication. This remains an area of active clinical interest.

The Wegovy pill and menopause-related weight gain

Weight gain during perimenopause and menopause is extremely common and often resistant to the dietary and lifestyle approaches that worked earlier in life. GLP-1 medications have emerged as a clinically meaningful option for women navigating menopausal weight changes, because they address the appetite and metabolic pathways that shifting hormones disrupt.

An oral option would be particularly welcome in this group, many women in their 40s and 50s are already managing multiple daily medications and would find a tablet significantly easier than a self-administered injection. When oral semaglutide does receive UK approval, it is likely to be one of the most discussed treatment options for weight management in this life stage.

Wegovy pill vs Wegovy injection: which is right for you?

Will the pill replace injections? Probably not.

Injectable GLP-1 medications are still expected to remain an important treatment option, and for some women they may continue to offer stronger or more consistent effects. Instead, oral semaglutide is more likely to increase treatment choice.

Some women may prefer injections because they are weekly rather than daily, because they fit more easily into routine, or because of how their body responds to treatment. Others may feel more comfortable starting with a tablet.

The future of obesity treatment will likely involve more personalised approaches, where treatment decisions are based on lifestyle, medical history, goals, preferences, side effect profile, and metabolic health needs.

Wegovy pill side effects: what women should know

The side effects are expected to be similar to injectable GLP-1 medications because the active ingredient is still semaglutide. Common side effects may include nausea, constipation, diarrhoea, bloating, reduced appetite, and fatigue.

As with injectable treatments, side effects often improve gradually over time, particularly with slower dose increases and appropriate clinical support.

Side effects of the Wegovy pill specific to women

Some evidence suggests women may be more susceptible to nausea-related side effects with GLP-1 medications, as female sex and a history of motion sickness are recognised predictors of nausea sensitivity in broader clinical research. GLP-1 medications can also slow gastric emptying, which may contribute to gastrointestinal symptoms such as nausea, bloating and vomiting. Individual tolerance can additionally be influenced by hormonal factors and differences in gut motility and the brain–gut axis. This is why personalised clinical oversight and gradual dose escalation can be important in supporting women to tolerate treatment successfully.

Oral semaglutide is not recommended during pregnancy or breastfeeding. Women with a personal or family history of thyroid conditions, pancreatitis, or eating disorders should discuss their suitability carefully with a clinician before starting.

What weight loss options are available to women in the UK right now?

At SheMed, we know that no single treatment approach works for everyone. While the Wegovy pill awaits UK approval, several licensed, clinically proven options are available to women today.

Wegovy injection: what it is and how it works

The Wegovy injection (semaglutide 2.4mg, once weekly) is licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related health condition. Clinical trials have demonstrated average weight loss of up to 28% of body weight. For women who want the clinical benefits of semaglutide now, the injection is the licensed, proven route.

Frequently asked questions about the Wegovy pill in the UK

Can I buy the Wegovy pill online in the UK?

No. There is no licensed Wegovy pill available to buy in the UK, online or otherwise. Any website claiming to sell oral semaglutide for weight loss in the UK is not selling a regulated product. Purchasing unlicensed medicines online carries serious health risks, including unknown ingredients, incorrect dosing, and no clinical oversight.

Is the Wegovy pill the same as Rybelsus?

Not exactly. Both contain oral semaglutide, but they are different products. Rybelsus is a lower-dose oral semaglutide licensed in the UK for type 2 diabetes, not weight loss. The Wegovy pill refers to a higher-dose formulation approved in the US specifically for chronic weight management. The two are related but not interchangeable.

Is oral semaglutide safe for women?

Clinical trial data has shown a safety profile broadly consistent with injectable semaglutide, with large numbers of female participants included in trials. Common side effects include nausea and gastrointestinal discomfort, particularly at the start of treatment. Oral semaglutide is not recommended during pregnancy or breastfeeding, and women with certain thyroid conditions, pancreatitis, or a history of eating disorders should seek careful clinical assessment before starting.

What is the difference between Wegovy and oral semaglutide?

Wegovy is the brand name for the injectable form of semaglutide (with dosing up to 7.2mg, once weekly) licensed for weight loss in the UK. Oral semaglutide is a tablet form of the same drug. Both work through the same GLP-1 mechanism but differ in how they are taken, how the drug is absorbed, and the dosing routine required. In the UK, only the injectable Wegovy is currently licensed for weight loss.

Will the NHS prescribe the Wegovy pill when it's approved?

This will depend on NICE guidance, which follows MHRA licensing. The Wegovy injection received a restricted NICE recommendation in 2023, limiting NHS prescribing to specialist weight management services. Oral semaglutide is likely to follow a similar pathway meaning NHS access may initially be limited, while private prescribing could become available more broadly.

What does this mean for you?

At SheMed, we know that no single treatment approach works for everyone. The potential arrival of oral GLP-1 medications reflects something important: weight management treatment is continuing to evolve, becoming more personalised, more accessible, and more focused on long-term metabolic health.

While injectable medications remain the current standard, the future may offer more flexibility and more choice in how treatment is delivered. As always, our focus remains on supporting women with evidence-based care, clinical oversight, personalised treatment, lifestyle support, and sustainable long-term health outcomes.

We will continue monitoring updates around oral semaglutide and will keep you informed as more information becomes available. In the meantime, if you would like to explore your current options with a clinician who understands women's health, start with a health check.

‍